Exploration of Targeted Anti-tumor Therapy’s Post

When combined with histological characteristics, molecular #biomarkers support a personalized treatment approach for endometrial cancer. Selecting treatments based on a patient’s biomarkers may help to not only maximize treatment benefits but also prevent treatment-related toxicities in patients whose #endometrialcancer is unlikely to respond to the therapies. Our featured experts explore this topic in this Expert Roundtables discussion with Alexander Olawaiye. From Expert Perspectives in Medicine

𝗛𝗼𝘄 𝗱𝗼 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗮𝗱𝗮𝗽𝘁𝗮𝘁𝗶𝗼𝗻𝘀 𝗰𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗲 𝘁𝗼 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻? Today's article explores metabolic adaptations in prostate cancer, highlighting how altered glucose metabolism, lipid metabolism, and one-carbon metabolism contribute to tumor progression and interactions with tumor microenvironment. It also highlights potential avenues for metabolism-related therapy. Key findings: • Prostate cancer cells exhibit enhanced glycolytic activity, which acidifies the tumor microenvironment and facilitates immune evasion. • Changes in lipid metabolism support tumor cell proliferation and enhance survival mechanisms. • One-carbon metabolism is crucial for regulating gene expression via DNA and histone methylation processes. • Metabolic adaptations influence interactions between cancer cells and the tumor microenvironment, impacting immune responses and remodeling of the extracellular matrix. I find the article extremely intriguing, offering insights into the intricate biochemical mechanisms that drive tumor progression and their implications for advancing therapeutic strategies. Full citation: Pujana-Vaquerizo, M., Bozal-Basterra, L. & Carracedo, A. Metabolic adaptations in prostate cancer. Br J Cancer (2024). https://lnkd.in/dRDPPdvi. Freely available under a Creative Commons license: https://lnkd.in/dyuva2r8 https://lnkd.in/dDtC9EzW #science #metabolism #pharmacology #precisionmedicine

Researchers from the University of North Carolina at Chapel Hill School of Medicine have gained insight into why T cells lose energy in solid tumors. T cells are known for their ability to hunt down cancer cells, but recent research has shown that they lose energy once they infiltrate the environment of a solid tumor, making it difficult for them to combat cancer. The research team led by Jessica Thaxton, Ph.D., MsCR, found that a metabolic enzyme called Acetyl-CoA Carboxylase (ACC) causes T cells to store fat rather than burn it for energy. Inhibiting the expression of ACC in mouse cancer models allowed T cells to persist much better in solid tumors. This discovery fills a gap in knowledge, providing a new understanding of how T cells operate in solid tumors. #Oncology&Cancer #Immunology

🧬American Society of Clinical Oncology (ASCO) Releases New Guidelines for Selection of Germline Genetic Testing Panels in Patients With Cancer🧬 Key Highlights: 📝 Detailed Family History: Collecting and recording family history is crucial for accurate testing and interpretation. 🧪 Multigene Panels: Offer comprehensive multigene panel testing for patients with relevant personal and family cancer history. 🔍 Integration with Tumor Testing: Ensure patients receive germline testing regardless of tumor test results, especially if pathogenic variants are found. Why It Matters: 🎯Precision Medicine: Tailored treatment plans based on genetic insights. 💖 Enhanced Care: Identifying hereditary cancer risks can improve patient and family outcomes. ⏳Timely Decisions: Rapid and accurate testing supports better therapeutic choices. Read the full guidelines here: https://lnkd.in/dzhGG5-s

Estrogen activated estrogen receptors are the highest regulators of cellular mechanisms and the blockade of ER activation is an emergency situation even in cancer cells.

Breast cancer 4 #Molecular_Aspect Exposure to #estrogen lead to DNA damage or gene mutation, Sometimes there will be an inheritance of DNA defects or pro-cancerous genes like BRCA1 and BRCA2. can be divided into #four_types based on molecular subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 (Her2) positive, and triple negative breast cancer (TNBC). #Her2 is reported to be overexpressed in 20–25% of breast cancers, which is associated with cancer cell aggressiveness. #TNBC, the most aggressive breast cancer, TNBC accounts for only 15–20% of breast cancers. However, it is usually identified at an advanced stage at the time of diagnosis, resulting in a high recurrence rate and low survival rate . Additionally, TNBC has no effective targeted therapy and most commonly metastasizes to the brain, bones, lungs, and liver. #breast_cancer #oncology #chemotherapy #drugs #pharmacy #pharmacist

FGFR fusions in thyroid cancer are important because they can act as primary oncogenic drivers, provide potentially actionable therapeutic targets, have prognostic significance, contribute to resistance mechanisms, and support personalized medicine. In this study, we investigated the role of FGFR alterations in thyroid carcinoma, identifying novel primary drivers and secondary events in tumor progression. Among 5,030 sequenced thyroid malignancies, 17 tumors exhibited FGFR alterations, with 11 driven by FGFR (n=9 gene fusions 4xFGFR2::VCL, 3xTG::FGFR1, FGFR2::CIT, FGFR2::SHTN1) or n=2 amplifications, and 6 showing FGFR as a secondary alteration. These findings highlight the potential therapeutic implications of targeting FGFR alterations, which are currently under-recognized and may offer novel treatment options for thyroid cancer patients – especially in light of several very successful novel FGFR inhibitor strategies emerging in intrahepatic cholangiocarcinoma. Pubmed entry: https://lnkd.in/easA9JJ5 DOI: 10.1089/thy.2024.0216 Publication: https://lnkd.in/eMQa-zE8 Image from: https://lnkd.in/edpUJKX5 Great teamwork by Mark Sabbagh, Tyler Janovitz MD, PhD, Dora Dias-Santagata, PhD, FACMG, Stephanie Siegmund, Valentina Nardi, Lori Wirth, gregory randolph, Brennan Decker, MD, PhD, Vania Nose, Bayan Alzumaili, Bill Faquin, Justine Barletta, Long Phi Le, John Iafrate, Peter Sadow, and amazing leadership by Adam Fisch #biomarker #personalizedmedicine #precisionmedicine #thyroidcancer #FGFR #predictive

Here's my review article on #Pharmacogenomics of #Prostate_cancer. #Precision_medicine is a game-changer for #prostate #cancer treatment. It recognizes that each patient's cancer is unique and uses advanced diagnostics and genetic testing to tailor treatments to their specific needs. This approach improves diagnosis accuracy, treatment efficacy, and reduces side effects. By acknowledging patient individuality, precision #medicine enables personalized care, addresses resistance and recurrence, and supports. https://lnkd.in/dV-HfQNM #Research #Review #science #cancer #personalized_medicine

CDK4/6 Inhibitors in Triple Negative Breast Cancer: A New Biomarker for Palbociclib Resistance Published on 2024 Jun Triple negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. While CDK4/6 inhibitors like palbociclib have shown promise, predicting their efficacy in TNBC remains a challenge. Key Findings: In vivo CRISPR Screen: A genome-wide CRISPR screen in TNBC identified TGFβ3 as a key gene influencing palbociclib sensitivity. TGFβ3 as a Biomarker: Low TGFβ3 levels correlate with palbociclib resistance in TNBC, offering a potential biomarker for patient selection. Synergistic Effect: Combining TGFβ3 with palbociclib enhances its anti-tumor effects, even in palbociclib-resistant cells. Mechanism of Action: TGFβ3 increases p21 expression, a cell cycle inhibitor, which enhances palbociclib's ability to induce cell cycle arrest. Clinical Implications: This discovery may lead to improved treatment strategies for TNBC, personalizing therapy based on TGFβ3 levels. Many thanks to: Sophie Poule, Meiou Dai, Ni Wan, Gang Yan, Julien Boudreault, Girija Daliah, Alan Guillevin, Huong Nguyen, Soaad Galal, Suhad Ali, Jean-Jacques Lebrun. Read the full research article here: https://lnkd.in/dAV8wmkd #TNBC #BreastCancer #CancerResearch #PersonalizedMedicine #DrugResistance #Biomarkers #CRISPR #TGFbeta #Palbociclib #CDK4/6inhibitors

Curcumin, a compound renowned for its antioxidant properties, is gaining attention as a potential cancer therapy. Research suggests that it could combat inflammation, a known factor in cancer development, and impede cancer's spread. Curcumin may also enhance the effectiveness of chemotherapy and protect healthy cells from radiation-induced damage. However, while preclinical studies are promising, human trials are still in their early stages. Ongoing investigations aim to evaluate curcumin's role in preventing cancer and alleviating cancer treatment-related symptoms. It's essential to note that current evidence doesn't support the widespread recommendation of curcumin. Stay updated with the latest research on cancer prevention and treatment. #CancerResearch #Curcumin #Antioxidant #Inflammation #Chemotherapy #RadiationTherapy #ClinicalTrials